iShares Nasdaq US Biotechnology UCITS ETF is an exchange-traded fund that seeks to track the performance of the Nasdaq Biotechnology Index, comprising Nasdaq-listed companies engaged in biomedical research to develop new treatments and cures for human diseases. Managed by BlackRock under the iShares brand and domiciled in Ireland, this UCITS-compliant ETF provides diversified exposure to the U.S. biotechnology and pharmaceutical sectors, adhering to strict EU regulations including the 5/10/40 diversification rule, liquidity requirements, and independent asset custody for investor protection. Launched on October 19, 2017, it employs a physical replication strategy in a long-only, accumulating format, reinvesting dividends to support compound growth without distributions. With a total expense ratio of 0.35% p.a. and a fund size exceeding EUR 781 million, it offers targeted access to innovative biotech firms driving advancements in healthcare, while remaining unhedged against currency fluctuations in its USD base. This ETF plays a key role in enabling European investors to participate in the dynamic biotechnology market through a transparent, regulated vehicle.